C. Martin Curtis

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock et al. · The Lancet · 2012 · 928 citations · Full text

Neuro-oncology, Untreated Brain Metastases, Medicine +7

Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

David Planchard, Tae Min Kim, Julien Mazières et al. · The Lancet Oncology · 2016 · 439 citations · Full text

Oncology, Non-small-cell Lung Cancer, Pathology +7

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green et al. · Gastroenterology · 2016 · 131 citations · Full text

Difference Between Latiglutenase, Villous Atrophy, Clinical Presentation +3

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

David A. Reardon, Morris D. Groves, Patrick Y. Wen et al. · Clinical Cancer Research · 2013 · 123 citations

Interim results of phase II study BRF113928 of dabrafenib in <i>BRAF</i> V600E mutation–positive non-small cell lung cancer (NSCLC) patients.

David Planchard, Julien Mazières, Gregory J. Riely et al. · Journal of Clinical Oncology · 2013 · 109 citations

Cancer Management, Pathology, Tumor Biology +17